| Mary Baker-berzansky, MD | |
|
2 Water St, Central Plaza, Haverhill, MA 01830-6223 | |
| (978) 556-0100 | |
| Not Available |
| Full Name | Mary Baker-berzansky |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 35 Years |
| Location | 2 Water St, Haverhill, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790782852 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 76761 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Anna Jaques Hospital | Newburyport, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Seacoast Affiliated Group Practice Inc | 1658357843 | 36 |
News Archive
MorphoSys AG today unveiled its next-generation antibody technology Ylanthia®. The technology was presented to an audience of specialists at the 2011 Antibody Engineering and Antibody Therapeutics Conference in San Diego. MorphoSys expects Ylanthia to set new standards for therapeutic antibody generation in the pharmaceutical industry over the next decade and beyond. Commercial application will commence in 2012.
OSI Pharmaceuticals, Inc. announced today its financial results for the Company's third quarter ended September 30, 2009. The Company reported total revenues from continuing operations of $111 million for the third quarter of 2009 compared to revenues of $95 million for the third quarter of 2008, an 18% increase over the prior year period.
The therapeutic potential of human induced pluripotent stem cells, which are capable of becoming almost any type of cell in the human body, is well-recognized and broadly pursued, but their mutational burden has not been fully characterized yet.
Children and adolescents who consistently watch television for 2 hours or more a day are at an increased risk of being overweight, to smoke, and to have high cholesterol concentrations in early adulthood—substantial risk factors for long-term health problems in later life—conclude authors of a study from New Zealand in this week's issue of THE LANCET.
Kaiser Health News staff writer Mary Agnes Carey reports on states' progress with high-risk pools created as part of the health reform law: "The program, one of the highest profile provisions of the law, is designed to provide health insurance to people who have been denied coverage due to a pre-existing medical condition and have been without coverage for at least six months.
› Verified 5 days ago
| Entity Name | Seacoast Affiliated Group Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801892344 PECOS PAC ID: 1658357843 Enrollment ID: O20040628001193 |
News Archive
MorphoSys AG today unveiled its next-generation antibody technology Ylanthia®. The technology was presented to an audience of specialists at the 2011 Antibody Engineering and Antibody Therapeutics Conference in San Diego. MorphoSys expects Ylanthia to set new standards for therapeutic antibody generation in the pharmaceutical industry over the next decade and beyond. Commercial application will commence in 2012.
OSI Pharmaceuticals, Inc. announced today its financial results for the Company's third quarter ended September 30, 2009. The Company reported total revenues from continuing operations of $111 million for the third quarter of 2009 compared to revenues of $95 million for the third quarter of 2008, an 18% increase over the prior year period.
The therapeutic potential of human induced pluripotent stem cells, which are capable of becoming almost any type of cell in the human body, is well-recognized and broadly pursued, but their mutational burden has not been fully characterized yet.
Children and adolescents who consistently watch television for 2 hours or more a day are at an increased risk of being overweight, to smoke, and to have high cholesterol concentrations in early adulthood—substantial risk factors for long-term health problems in later life—conclude authors of a study from New Zealand in this week's issue of THE LANCET.
Kaiser Health News staff writer Mary Agnes Carey reports on states' progress with high-risk pools created as part of the health reform law: "The program, one of the highest profile provisions of the law, is designed to provide health insurance to people who have been denied coverage due to a pre-existing medical condition and have been without coverage for at least six months.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mary Baker-berzansky, MD 2 Water St, Central Plaza, Haverhill, MA 01830-6223 Ph: (978) 556-0100 | Mary Baker-berzansky, MD 2 Water St, Central Plaza, Haverhill, MA 01830-6223 Ph: (978) 556-0100 |
News Archive
MorphoSys AG today unveiled its next-generation antibody technology Ylanthia®. The technology was presented to an audience of specialists at the 2011 Antibody Engineering and Antibody Therapeutics Conference in San Diego. MorphoSys expects Ylanthia to set new standards for therapeutic antibody generation in the pharmaceutical industry over the next decade and beyond. Commercial application will commence in 2012.
OSI Pharmaceuticals, Inc. announced today its financial results for the Company's third quarter ended September 30, 2009. The Company reported total revenues from continuing operations of $111 million for the third quarter of 2009 compared to revenues of $95 million for the third quarter of 2008, an 18% increase over the prior year period.
The therapeutic potential of human induced pluripotent stem cells, which are capable of becoming almost any type of cell in the human body, is well-recognized and broadly pursued, but their mutational burden has not been fully characterized yet.
Children and adolescents who consistently watch television for 2 hours or more a day are at an increased risk of being overweight, to smoke, and to have high cholesterol concentrations in early adulthood—substantial risk factors for long-term health problems in later life—conclude authors of a study from New Zealand in this week's issue of THE LANCET.
Kaiser Health News staff writer Mary Agnes Carey reports on states' progress with high-risk pools created as part of the health reform law: "The program, one of the highest profile provisions of the law, is designed to provide health insurance to people who have been denied coverage due to a pre-existing medical condition and have been without coverage for at least six months.
› Verified 5 days ago
Dr. Christannah M Waters, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 62 Brown St, Suite 405, Haverhill, MA 01830 Phone: 978-912-7450 Fax: 978-912-7420 | |
Jane Kerr-fernandez, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 600 Primrose St Ste 202, Haverhill, MA 01830 Phone: 978-556-1000 Fax: 978-556-0101 | |
Steven Mollov, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 600 Primrose St Ste 202, Haverhill, MA 01830 Phone: 978-556-1000 Fax: 978-556-0100 | |
Ms. Mary C. Chang, D.O. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 600 Primrose St Ste 202, Haverhill, MA 01830 Phone: 978-556-1000 Fax: 978-556-0094 | |
Dr. Melinda Ropar Birdsall, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 62 Brown Street Suite 202, Merrimack Valley Gynecology, Haverhill, MA 01830 Phone: 978-914-7736 Fax: 978-702-4432 | |
Celeste Royce, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2 Water St, Central Plaza, Haverhill, MA 01830 Phone: 978-556-0100 | |
Susan Newhouse, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2 Water St, Central Plaza, Haverhill, MA 01830 Phone: 978-556-0100 |